ISIS 104838

· Ionis Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ISIS 104838, covering 2022-12-05 to 2022-12-05. Get the full timeline:

Most recent: Clinical Trial Update: ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis [Phase 2]